RFA-AI-22-071 Autoimmunity Centers of Excellence, Clinical Research Program (UM1 Clinical Trial Required)

Application Due Date: May 19, 2023

Funder: NIH National Institute of Allergy and Infectious Diseases (NIAID)

 
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to participate in the NIAID Autoimmunity Centers of Excellence (ACE), a cooperative network intended to improve the understanding, prevention, and treatment of autoimmune diseases. The ACE program was founded on the premise that collaborations among basic and clinical scientists can accelerate both fundamental and applied research. The ACE combines Basic and Clinical research programs. This FOA solicits applications for the Clinical research program; a companion FOA solicits applications for the Basic research program. Members of the Clinical research program will conduct innovative studies of human autoimmunity within Clinical and Collaborative Projects. Members of the Basic and Clinical ACE will work together to design and conduct studies of autoimmune disease pathogenesis and mechanisms of action of immune-modulating interventions being tested in ACE clinical trials.

Learn More Contact OSR to Apply

Topics: Clinical Presentation of Infection, ARDS, Cellular / Molecular Response, Inflammation, Long-term Impact of Infection, Pneumonia, Sensory, Clinical Trial, Co-Morbidities, COVID-19, Diabetes, Immune Disorders, HIV, Immunosuppression, Rheumatoid Disorders, Community Engagement, Computational Analysis, Computational or Data Science Methods Development, Epidemiology, Clinical History, Clinical Outcome, Incidence, Risk Factors, Health Disparities, Immunity, Immunology, Host Factors, Host Response, Prognostics, Virology, Viral Interactome, Vaccine Development, Vaccine Efficacy, Vaccine Reliability, Vaccine Scalability, Treatments, Treatment Efficacy, Treatment Reliability, Treatment Scalability, Drugs, Antibody-based Treatment, Convalescent Serum, Drug Development, Drug Targets, Immunological Response Targets, Anti-viral Targets